A cocktail of PEG engagers with specificity to different tumour-associated antigens (for example, insulin-like growth factor 1 receptor, HER2, HER3, HER4 and c-Met) might offer a flexible yet effective treatment option for heterogeneous tumours. The gene discussed is ERBB3; the disease is neoplasm.